US FDA Commissioner Scott Gottlieb intends to reorganize drug reviewers from multiple disciplines into teams that would handle a product's entire life-cycle, an attempt to break down the siloed nature of many areas within the agency.
Gottlieb Promotes 'Team' Work For Product Reviews
US FDA Commissioner intends to change agency's siloed structure and move reviewers into teams that will follow products pre- and post-market.